Score Pharma, Inc.

Score leverages the power of small-molecule pharmacology to develop ADCC enhanced monoclonal antibody therapeutics for a better patient response

  • Stage Product In Development
  • Industry Biotechnology
  • Location Huntsville, AL, USA
  • Currency USD
  • Founded May 2018
  • Employees 1
  • Incorporation Type C-corp
  • Website scorepharma.com

Company Summary

Score uses its proprietary CoreX technology to rapidly develop an ADCC improved version of existing validated monoclonal antibody (mAb) therapeutics. We intend to develop the new ADCC improved version to Phase 1 clinical and then out-license for further development. The use of existing products capitalizes on existing markets and increases the probability of success since the original product established a validated use and clinical path forward.

Team

  • Bruce Jones
    Founder/President/CEO

    Over 30 years experience in Pharmaceutical / Biopharmaceutical Industry; Experienced with major and specialty pharmaceutical environments; Directed drug discovery and disease biology groups;
    Lead CNS stroke/trauma and oncology discovery teams at Cephalon and Regeneron

  • Steven Feder
    Co-Founder / Board Member / Secretary

    Over 30 years experience as a life sciences executive/attorney; Extensive record of early-stage company development/growth; Financings (equity, debt, angels/institutions/VC) and partnering/M&A; Skilled in finance, HR, outsourcing, IP strategy, Board support, compliance and record-keeping

  • Martina Molsbergen
    Co-Founder / VP - Business Development

    Martina has closed over 17 out-licensing deals for genetic modification ADCC enhancement technology; Several deals have resulted in products generating multi-billion dollar revenue streams.

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free